新华社南昌12月12日电 题：内陆小镇何以"公交出海" 新华社记者陈柱佐 走进江西省南昌县的江西三鑫医疗科技股份有限公司生产车间，一个个500毫升矿泉水瓶大小的血液透析耗材在生产线上有序组装、封 装、打包。一周后，这批产品将从南昌国际陆港搭乘外贸班列，经由厦门港转货轮后运往泰国。 "相较于公路汽运，铁海联运'天天班'每个标箱可节省2500元左右的物流成本。"张谞杰说，今年前11个月，公司共发出392个标箱，较去年 同期增长52.3%，"天天班"像公交一样定时定点、方便省心，有效帮助公司降本增效，促进外贸发展。 南昌铁路物流中心营销部经理杨波介绍，"天天班"是一种以公交化运营模式开行的货运班列，班列每日按既定时刻发车，沿固定线路运 行，实现"按点发货、按约送达"的标准化服务，解决以往"货等车""船等货"的难题，可以实现18至24小时直达港口，构建"门到港"高效物流生 态。 和张谞杰有同样感受的还有江西展宏农业发展有限公司总经理高昕。他介绍，受本地农作物生长周期影响，农资化肥市场存在淡旺季之 分，过去公司每年一般只生产7个月，包括冬季在内的5个月基本停工。记者近日走进企业看到，即使处于淡季，厂房里生产运转如常，一 ...

Core Viewpoint - Company is focusing on international expansion as a strategic initiative, leveraging the opportunity of "Chinese manufacturing" going global, and has successfully registered products in countries like Indonesia, Peru, and Mexico while accelerating certification processes in Turkey, Vietnam, and Brazil [1] Group 1: International Expansion - Company has established a global self-certification system to enhance its international market presence in the blood purification business, significantly improving its global competitiveness [1] - By the first half of 2025, the company achieved notable results in overseas market development, with overseas business revenue reaching 187 million yuan, representing a year-on-year growth of 67.30% [1] Group 2: Product Performance - Revenue from blood purification product exports reached 165 million yuan, accounting for 88% of total export revenue, with a year-on-year increase of 83.84% [1] - In the first half of 2025, export sales revenue of hemodialysis equipment grew by approximately 130%, while export sales revenue of hemodialysis consumables increased by about 70% [1] - The stable growth of key product exports has become a significant driver of the company's performance [1]

Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. reported a revenue of 761 million yuan in the first half of 2023, marking a year-on-year increase of 10.83%, with a net profit of 115 million yuan, up 8.35% year-on-year [2] Group 1: Financial Performance - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, was 103 million yuan, reflecting a year-on-year growth of 9.26% [2] - Revenue from blood purification products reached 626 million yuan, representing a year-on-year increase of 19.73%, accounting for 82.23% of total revenue [3] - The gross margin for blood purification products was 34.30%, showing an increase compared to the previous year [4] Group 2: Market Expansion - The company achieved significant breakthroughs in overseas markets, with international sales revenue reaching 187 million yuan, a year-on-year increase of 67.30% [6] - Blood purification product exports contributed 165 million yuan to overseas sales, accounting for 88% of total export revenue, with an increase of 83.84% year-on-year [6] - The company is focusing on emerging markets along the "Belt and Road" initiative, which have large and growing populations, providing substantial market opportunities [6] Group 3: Industry Trends - The global end-stage renal disease (ESRD) patient population is projected to grow from 11.14 million in 2023 to 13.29 million by 2027, with a compound annual growth rate of 4.51% [3] - The demand for blood purification products is expected to remain strong due to the increasing number of ESRD patients and the essential nature of these products in treatment [4][3]

Core Viewpoint - Company is accelerating its internationalization process and capitalizing on the historical opportunity of "Chinese manufacturing" going global, successfully completing product registrations in countries like Indonesia, Peru, and Mexico, while also advancing certification processes in Turkey, Vietnam, and Brazil [1] Group 1: International Expansion - Company has obtained over a hundred overseas registration certificates for its products, enhancing its global competitiveness and laying a solid foundation for brand globalization [1] - The overseas business achieved revenue of 187 million yuan, representing a year-on-year growth of 67.30% [1] Group 2: Product Performance - Blood purification products accounted for 88% of total export revenue, with sales revenue of 165 million yuan, marking an increase of 83.84% year-on-year [1] - Export sales revenue for blood dialysis equipment grew by approximately 130% year-on-year, while sales revenue for blood dialysis consumables increased by about 70% year-on-year [1] Group 3: Growth Drivers - The stable growth of key product exports has become a significant driver of the company's performance [1]

Core Viewpoint - The company is accelerating its internationalization process and capitalizing on the historical opportunity of "Chinese manufacturing" going global, achieving significant growth in overseas markets [1] Group 1: International Expansion - The company has successfully completed product registrations in Indonesia, Peru, and Mexico, and is advancing certification processes in Turkey, Vietnam, and Brazil [1] - Over 100 products have obtained overseas registration certificates, enhancing the company's global competitiveness and laying a solid foundation for brand globalization [1] Group 2: Financial Performance - Overseas business revenue reached 187 million yuan, representing a year-on-year growth of 67.30% [1] - Blood purification product exports accounted for 88% of total export revenue, with sales revenue of 165 million yuan, up 83.84% year-on-year [1] - Export sales revenue for blood dialysis equipment increased by approximately 130%, while sales revenue for blood dialysis consumables grew by about 70% [1] Group 3: Future Strategy - The company plans to accelerate the self-certification process in more countries and strengthen deep cooperation with key customers to further expand overseas markets [1]

Group 1 - The report provides a comprehensive overview of the blood dialysis consumables industry, including definitions, classifications, and regulatory frameworks [4] - It outlines the macro environment analysis of the blood dialysis consumables industry in China, focusing on policy, economic, social, and technological factors [5] - The report discusses the global development status and market trends of the blood dialysis consumables industry, including historical development and macro environment background [6] Group 2 - The impact of the COVID-19 pandemic on the global blood dialysis consumables industry is analyzed, highlighting changes in market dynamics [6] - The report examines the supply and demand conditions in the Chinese blood dialysis consumables market, identifying key pain points and trade status [6][7] - It includes a competitive landscape analysis of the Chinese blood dialysis consumables industry, assessing market concentration and competitive forces [7] Group 3 - The report details the investment and financing conditions within the Chinese blood dialysis consumables industry, including mergers and acquisitions [7] - It provides insights into the industry structure and value chain analysis, highlighting the roles of upstream suppliers and midstream market segments [8][9] - The report concludes with a market forecast and strategic investment recommendations for the blood dialysis consumables industry in China [10]